Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total World Stock Index Fund ETF (VT) vs Viatris Inc (VTRS) Price & Performance

Vanguard Total World Stock Index Fund ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Total World Stock Index Fund ETF vs Viatris Inc — how do they compare? Vanguard Total World Stock Index Fund ETF trades at $159.69 (market cap $101.70B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 5.1× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total World Stock Index Fund ETF for 53 Days and Viatris Inc for 57 Days on average.

VTVTRS
Market Cap
$101.70B$20.03B
Volume
1,783,79414,109,977
Sector
Broad Market / FactorHealth
52-Week High
$162.39$18.27
52-Week Low
$134.19$9.74
Typical Hold Time
53 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total World Stock Index Fund ETF

Vanguard Total World Stock ETF (VT) trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains strong global diversification with over 9,700 holdings across developed and emerging markets. Recent news highlights VT's competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF, with analysts noting its comprehensive exposure and long-term performance advantages.

VT offers investors broad global equity exposure with low costs, though its expense ratio of 0.06% faces pressure from cheaper alternatives. The ETF's performance remains tied to global economic conditions, with risks including trade policy uncertainty and currency fluctuations. Analyst sentiment is generally positive for long-term diversification strategies.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VT
95% Buy5% Sell
Avg holding period · 53 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Vanguard Total World Stock Index Fund ETF

VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.

Read more on VT →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →